Magellan Health, Inc. (NASDAQ:MGLN) reported Q2 2017 earnings this Morning, coming in at $0.59 per share, missing Wall Street’s estimates of $1.16 per Share. Revenue for the quarter came in at $1.42 billion beating analyst estimates of $1.40 billion
Analyst Coverage For Magellan Health, Inc. (NASDAQ:MGLN)
These are 1 Sell Rating, 3 Buy Ratings .
The current consensus rating for Magellan Health, Inc. (NASDAQ:MGLN) is Buy (Score: 2.50) with a consensus target price of $80.25 , a potential (1.84% upside)Recent Insider Trading for Magellan Health, Inc. (NASDAQ:MGLN)
- On 7/25/2017 Daniel N Gregoire, General Counsel, sold 4,559 with an average share price of $80.68 per share and the total transaction amounting to $367,820.12.
- On 7/24/2017 Daniel N Gregoire, General Counsel, sold 33,574 with an average share price of $80.11 per share and the total transaction amounting to $2,689,613.14.
- On 7/20/2017 Daniel N Gregoire, General Counsel, sold 16,073 with an average share price of $80.06 per share and the total transaction amounting to $1,286,804.38.
- On 7/20/2017 Jeffrey N West, SVP, sold 1,109 with an average share price of $80.01 per share and the total transaction amounting to $88,731.09.
- On 7/17/2017 Jeffrey N West, SVP, sold 28,514 with an average share price of $80.07 per share and the total transaction amounting to $2,283,115.98.
- On 7/14/2017 Daniel N Gregoire, General Counsel, sold 14,114 with an average share price of $80.11 per share and the total transaction amounting to $1,130,672.54.
Recent Trading for Magellan Health, Inc. (NASDAQ:MGLN) Shares of Magellan Health, Inc. closed the previous trading session at 73.40 down -5.40 -6.85% with 186,959 shares trading hands.